Nanjing Reju Therapeutics Inc. has described tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) inhibitors reported to be useful for the treatment of inflammatory-related disorders and cell necrosis-related apoptosis diseases.
Universitat de Barcelona has identified histone-lysine N-methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors reported to be useful for the treatment of Alzheimer’s disease among others.
A recent study by researchers at the University of Florence and collaborators has demonstrated the efficacy of MRS-3997, a dual adenosine A2A/A2B receptor agonist, in reducing brain damage and inflammation in a rat model of ischemic stroke.
The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes medications, individuals with a prescription for GLP-1RAs had a reduced risk of 42 diseases, and an increased risk of 19. The findings, which were published Jan. 20, 2025, in Nature Medicine, provide a comprehensive overview of GLP-1RAs’ effects.
Jiangsu Nhwa Pharmaceutical Co. Ltd. has patented substituted imidazole derivatives acting as α2-adrenoceptor agonists with sedative and/or analgesic and/or anesthetic and/or anxiolytic activity. As such, they are reported to be potentially useful for the treatment of pain, insomnia and psychiatric disorders.
Having 35 copies of the CAG triplet in the gene that causes Huntington’s disease is not a problem. Inheriting 40 could be a sign that goes unnoticed for decades, until reaching 80. From there, the process accelerates and neural death occurs when reaching 150 repeats. Huntington’s disease neurodegeneration is not determined by what, but by how much, according to a study conducted at the Broad Institute.
A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders and cognitive disorder.
T-cell leukemia homeobox protein 3 (TLX3) is a key regulator of fate specification of excitatory neurons and found expressed in proliferating granule neuron progenitors (GNPs) of the cerebellum, but its main role is not well known.
Pheno Therapeutics Ltd. has received clinical trial authorization (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its lead candidate, PTD-802. The program will progress to a first-in-human phase I trial.
RSS
